Rydex S&P 500 Pure Value H
RYZAX
NASDAQ- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Rydex S&P 500 Pure Value Fund Class H (RYZAX) is an open-end mutual fund that seeks to provide investment results corresponding to the daily performance of the S&P 500 Pure Value Index, before fees and expenses. The fund invests primarily in securities comprising the benchmark index, which focuses on large-cap U.S. value stocks exhibiting the strongest value traits based on metrics such as book value-to-price, earnings-to-price, and sales-to-price ratios; it maintains approximately 98.85% allocation to U.S. stocks across sectors including healthcare (19.57%), financial services (17.15%), consumer cyclical (15.50%), consumer defensive (14.77%), and energy (8.98%). Available to U.S. investors with a minimum initial investment of $2,500, the fund features a net expense ratio of 1.55%-1.56%, annual distributions when applicable, and no front-end or deferred loads. Launched on February 20, 2004, and headquartered in the United States under the management of Guggenheim Investments through its affiliate Security Investors, LLC as investment adviser and Guggenheim Funds Distributors, LLC as distributor, RYZAX operates as a Rydex-branded fund domiciled in the U.S. with total net assets of approximately $8.96 million and share class assets of $5.45 million. The investment team includes Michael Byrum since inception, joined by Brendan Cain, Spencer Crane, and Scott Miller effective July 8, 2022. The fund targets individual and institutional investors seeking mid- to large-cap value exposure aligned with the Large Value Morningstar category. Recent portfolio dynamics reflect market shifts, with top holdings including CVS Health Corp (2.68%-3.51%), Centene Corp (2.64%), General Motors Co (2.41%-2.92%), Ford Motor Co (2.40%-2.79%), and Archer-Daniels-Midland Co (2.19%-2.66%), comprising about 12.32% of assets as of late 2025. No major acquisitions, funding rounds, partnerships, new product launches, or strategic reorganizations have been announced for the fund within the last 1-2 years; it continues steady daily tracking of its benchmark amid Guggenheim Partners' ongoing oversight of Rydex fund family operations.